Hypertrophic cardiomyopathy - 2014 Review article
Article Sidebar
Main Article Content
Abstract
In 2014 European Cardiac Society has issued the new guidelines on the diagnosis and management of hypertrophic cardiomyopathy (HCM). This article summarizes the most important changes in the approach to HCM, in comparison to ESC Guidelines from 2003 and the latest American Guidelines from 2011.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. Circulation 2011; 24(24): e783-831.
3. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur. Heart J. 2014; 35(39): 2733-2779.
4. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). O’Mahony C., Jichi F., Pavlou M. et al.; Hypertrophic Cardiomyopathy Outcomes Investigators. Eur. Heart J. 2014; 35(30): 2010-2020.
5. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur. Heart J. 2011; 32(24): 3147-3197.